{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:07:17Z","timestamp":1777518437782,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1016\/j.rdc.2005.10.003","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T10:09:23Z","timestamp":1168423763000},"page":"235-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Newer Therapeutic Approaches: Gout"],"prefix":"10.1016","volume":"32","author":[{"suffix":"Jr","given":"H. Ralph","family":"Schumacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.rdc.2005.10.003_bib1","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","article-title":"Management of acute and chronic gouty arthritis: present state-of-the art","volume":"64","author":"Schlesinger","year":"2004","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.rdc.2005.10.003_bib2","first-page":"336","article-title":"Diagnosis and management of gout","volume":"10","author":"Chen","year":"2003","journal-title":"J Clin Outcomes Manage"},{"issue":"17","key":"10.1016\/j.rdc.2005.10.003_bib3","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMcp030733","article-title":"Clinical practice. Gout","volume":"349","author":"Terkeltaub","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2005.10.003_bib4","series-title":"Evidence based rheumatology","first-page":"65","article-title":"Gout","author":"Schlesinger","year":"2004"},{"issue":"3","key":"10.1016\/j.rdc.2005.10.003_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1445-5994.1987.tb01232.x","article-title":"Does colchicine work? The results of the first controlled study in acute gout","volume":"17","author":"Ahern","year":"1987","journal-title":"Aust N Z J Med"},{"issue":"4","key":"10.1016\/j.rdc.2005.10.003_bib6","first-page":"231","article-title":"What is the optimal treatment for acute crystal-induced arthritis?","volume":"63","author":"Pawlotsky","year":"1996","journal-title":"Rev Rhum Engl Ed"},{"issue":"3","key":"10.1016\/j.rdc.2005.10.003_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/art.11056","article-title":"Aspiration and injection therapies for joints","volume":"49","author":"Schumacher","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2005.10.003_bib8","first-page":"331","article-title":"Local ice therapy during bouts of acute gouty arthritis","volume":"29","author":"Schlesinger","year":"2002","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2005.10.003_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.rdc.2005.10.003_bib10","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.60.10.981","article-title":"Relation between adverse events associated with allopurinol and renal function in patients with gout","volume":"60","author":"Vazquez-Mellado","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2005.10.003_bib11","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2005.10.003_bib12","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1592\/phco.24.17.1784.52334","article-title":"Colchicine myotoxicity: Case reports and literature review","volume":"24","author":"Wilbur","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.rdc.2005.10.003_bib13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1016\/j.rdc.2005.10.003_bib14","first-page":"S335","article-title":"A phase 2, long term, open-label safety and efficacy study of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase","volume":"50","author":"Schumacher","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2005.10.003_bib15","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urates stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2005.10.003_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/1529-0131(200101)44:1<231::AID-ANR30>3.0.CO;2-7","article-title":"Efficacy and safety of desensitization to allopurinol following cutaneous reaction","volume":"44","author":"Fam","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2005.10.003_bib17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00124743-200010000-00006","article-title":"Desensitization to allopurinol after allopurinol hypersensitivity syndrome with renal involvement in gout","volume":"6","author":"Vazquez-Mellado","year":"2000","journal-title":"J Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2005.10.003_bib18","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.rdc.2005.10.003_bib19","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.amjmed.2005.03.043","article-title":"Serum uric acid and cardiovascular disease: recent development and where do they leave us?","volume":"118","author":"Baker","year":"2005","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.rdc.2005.10.003_bib20","first-page":"906","article-title":"Serum uric acid concentration as a risk factor for cardiovascular mortality: a long term cohort study of atomic bomb survivors","volume":"32","author":"Hakoda","year":"2005","journal-title":"J Rheumatol"},{"issue":"14","key":"10.1016\/j.rdc.2005.10.003_bib21","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/archinte.164.14.1546","article-title":"Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study","volume":"164","author":"Niskanen","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rdc.2005.10.003_bib22","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1523-1755.2004.00484.x","article-title":"The impact of serum uric acid on cardiovascular outcomes in the LIFE study","volume":"65","author":"Hoieggen","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.rdc.2005.10.003_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJM197802092980601","article-title":"Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. The Anturane Reinfarction Trial","volume":"298","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2005.10.003_bib24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1056\/NEJM198001313020502","article-title":"Sulfinpyrazone in the prevention of sudden death after myocardial infarction. The Anturane Reinfarction Trial Research Group","volume":"302","year":"1980","journal-title":"N Engl J Med"},{"issue":"8266","key":"10.1016\/j.rdc.2005.10.003_bib25","first-page":"237","article-title":"Sulphinpyrazone in post-myocardial infarction. Report from the Anturan Reinfarction Italian Study","volume":"1","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2005.10.003_bib26","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJM198204223061640","article-title":"reevaluation of outcome","volume":"306","year":"1982","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2005.10.003_bib27","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.rdc.2005.10.003_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5694\/j.1326-5377.2003.tb05474.x","article-title":"Aspirin for cardiovascular disease prevention","volume":"179","author":"Hung","year":"2003","journal-title":"Med J Aust"},{"issue":"Suppl 2","key":"10.1016\/j.rdc.2005.10.003_bib29","doi-asserted-by":"crossref","first-page":"ii17","DOI":"10.1136\/hrt.2005.062042","article-title":"Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction","volume":"91","author":"Weir","year":"2005","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.rdc.2005.10.003_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00124743-200212000-00003","article-title":"Effect of minidose aspirin on renal function and renal uric acid handing in healthy young adults","volume":"8","author":"Louthrenoo","year":"2002","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2005.10.003_bib31","first-page":"773","article-title":"Gout: excess calories, purines and alcohol intake and beyond. Response to a urate-lowering diet","volume":"32","author":"Fam","year":"2005","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2005.10.003_bib32","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/0002-9343(74)90634-2","article-title":"Milestones in the treatment of gout","volume":"56","author":"Yu","year":"1974","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.rdc.2005.10.003_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/art.20761","article-title":"Intake of purine rich foods, proteins and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey","volume":"52","author":"Choi","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2005.10.003_bib34","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/jn\/133.6.1826","article-title":"Consumption of cherries lowers plasma urate in healthy women","volume":"133","author":"Jacob","year":"2003","journal-title":"J Nutr"},{"issue":"4","key":"10.1016\/j.rdc.2005.10.003_bib35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.7326\/0003-4819-84-4-385","article-title":"Ascorbic acid-induced uricosuria. A consequence of megavitamin therapy","volume":"84","author":"Stein","year":"1976","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.rdc.2005.10.003_bib36","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/ard.33.3.276","article-title":"Effect of oral fructose on urate production","volume":"33","author":"Emmerson","year":"1974","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2005.10.003_bib37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0026-0495(72)90120-5","article-title":"Studies on the mechanism of fructose-induced hyperuricemia in man","volume":"21","author":"Fox","year":"1972","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.rdc.2005.10.003_bib38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/ard.59.7.539","article-title":"Beneficial effects of weight loss associated with moderate calorie\/carbohydrate restriction, and proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study","volume":"59","author":"Dessein","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2005.10.003_bib39","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s11926-996-0043-1","article-title":"Diet, alcohol and gout: how do we advise patients given recent developments?","volume":"7","author":"Choi","year":"2005","journal-title":"Curr Rheumatol Rep"},{"issue":"12","key":"10.1016\/j.rdc.2005.10.003_bib40","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.1780311211","article-title":"Suppression of monosodium urate crystal-induced acute inflammation by diets enriched with gamma-linolenic acid and eicosapentaenoic acid","volume":"31","author":"Tate","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2005.10.003_bib41","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/art.20102","article-title":"Quality of care indicators for gout management","volume":"50","author":"Mikuls","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.10.003_bib42","first-page":"77","article-title":"How does patient education affect gout?","volume":"2","author":"Murphy-Bielicki","year":"1984","journal-title":"Clin Rheumatol Pract"},{"issue":"7352","key":"10.1016\/j.rdc.2005.10.003_bib43","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/bmj.324.7352.1488","article-title":"Randomized double blind trial of etoricoxib and indometacin in the treatment of acute gouty arthritis","volume":"324","author":"Schumacher","year":"2002","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.rdc.2005.10.003_bib44","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.20007","article-title":"Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial","volume":"50","author":"Rubin","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2005.10.003_bib45","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.leu.2402847","article-title":"Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas 2002","volume":"17","author":"Navolanic","year":"2003","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.rdc.2005.10.003_bib46","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11926-004-0075-3","article-title":"Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase","volume":"6","author":"Bomalaski","year":"2004","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"10.1016\/j.rdc.2005.10.003_bib47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/ndt\/gfh629","article-title":"Urate oxidase (rasburicase) for treatment of severe tophaceous gout","volume":"20","author":"Vogt","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.rdc.2005.10.003_bib48","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1373\/49.8.1417","article-title":"Sample preparation in patients receiving uric acid oxidase (rasburicase) therapy","volume":"49","author":"Lim","year":"2003","journal-title":"Clin Chem"},{"issue":"9","key":"10.1016\/j.rdc.2005.10.003_bib49","first-page":"1942","article-title":"Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies","volume":"29","author":"Bomalaski","year":"2002","journal-title":"J Rheumatol"},{"issue":"Suppl","key":"10.1016\/j.rdc.2005.10.003_bib50","first-page":"S337","article-title":"A Phase I study of pegylated uricase (Puricase\u00ae) in subjects with gout","volume":"50","author":"Sundy","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1016\/j.rdc.2005.10.003_bib51","first-page":"S338","article-title":"Antibodies in polyethylene glycol (PEG) during Phase 1 investigation of PEG urate oxidase (PEG-uricase; Puricase\u00ae) for refractory gout","volume":"50","author":"Garson","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2005.10.003_bib52","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"8\u20139","key":"10.1016\/j.rdc.2005.10.003_bib53","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1081\/NCN-200027377","article-title":"PK\/PD and safety of a single dose of TMX-67 (Febuxostat) in subjects with mild and moderate renal impairment","volume":"23","author":"Hoshide","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.rdc.2005.10.003_bib54","first-page":"S336","article-title":"Magnetic resonance imaging of a gouty tophi during treatment with febuxostat, a non-purine selective inhibitor of xanthine oxidase","volume":"50","author":"Schumacher","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.10.003_bib55","first-page":"S336","article-title":"Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, therapy in allopurinol intolerant patients","volume":"50","author":"Becker","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.rdc.2005.10.003_bib56","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1097\/00004872-200110000-00021","article-title":"Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaema and gout","volume":"19","author":"Wurzner","year":"2001","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.rdc.2005.10.003_bib57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1161\/01.HYP.26.1.112","article-title":"Effects of losartan on a background of hydrochlorothiazide in patients with hypertension","volume":"26","author":"Soffer","year":"1995","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.rdc.2005.10.003_bib58","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.62.6.572","article-title":"Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and\/or losartan on uric acid metabolism","volume":"62","author":"Takahashi","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2005.10.003_bib59","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/keg103","article-title":"Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout","volume":"42","author":"Feher","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.rdc.2005.10.003_bib60","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1093\/ndt\/gfg341","article-title":"Amlodipine reduces cyclosporine-induced hyperuricaemia in hypertensive renal transplant recipients","volume":"18","author":"Chanard","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.rdc.2005.10.003_bib61","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/art.20781","article-title":"Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis. A randomized clinical trial","volume":"52","author":"Garg","year":"2005","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X05000918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X05000918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:05:11Z","timestamp":1760180711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X05000918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S0889857X05000918"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2005.10.003","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Newer Therapeutic Approaches: Gout","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2005.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}